Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: December 3, 2025
Reporting Period: Event-specific report dated December 3, 2025.
Business Overview: The company is a Delaware corporation focused on noninvasive diagnostic testing, specifically the CyPath® Lung test, a sputum-based flow cytometry test for lung cancer detection.
Key Financial Metrics
This filing is an "Other Events" report (Item 8.01) and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes
No material financial changes or operational shifts are reported in this document. The filing solely announces a corporate event regarding the presentation of clinical data.
Outlook, Management Commentary, and Risks
- Event Announcement: On December 3, 2025, the company announced it will present a poster titled "CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence" at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025.
- Clinical Data Highlight: The poster showcases three cases where the CyPath® Lung test successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations.
- Management Commentary: The filing incorporates a press release and the poster itself as exhibits but does not include direct narrative commentary from management beyond the event announcement.
- Risks and Contingencies: No specific risks or contingencies are detailed in this 8-K filing.
Investor Verification Checklist
- Verify the content and clinical validity of the poster presented at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025.
- Review the attached press release (Exhibit 99.1) for additional context on the three case studies mentioned.
- Monitor subsequent filings for any financial impact or strategic decisions resulting from the clinical data presentation.
- Confirm the company's status as an emerging growth company and its compliance with related reporting standards.